Investor relations
Dicot Pharma develops LIB-01 into a new potency drug that aims to become the first choice globally for the treatment of erectile dysfunction and premature ejaculation.
LIB-01 is in the clinical development phase, where a clinical phase 1 study was completed with very good results in Q2 2024. A phase 2a study started in November 2024.
Development is intended to be carried out under own auspices up to and including clinical phase 2a and then together with major pharmaceutical companies to introduce LIB-01 to the world market.
Dicot Pharma has approximately 8,100 shareholders. Its share and warrant series TO6 are listed on Nasdaq First North Stockholm. The share was first listed in 2018 on Spotlight Stock Market.
Nasdaq requires that all companies whose shares are admitted to trading on Nasdaq First North must engage a specially approved adviser who acts as a support for the companies and as an intermediary in contact with Nasdaq, a so-called Certified Adviser. Dicot Pharma engages FNCA Sweden AB for the role of Certified Adviser. Contact details: FNCA Sweden AB, Box 5216, SE-102 45 Stockholm, Sweden. Phone + 46 8 528 00 399. E-mail [email protected].
IR contact
